 |
A Multidisciplinary Discussion of Issues Related to Generic Drug Substitution in People With Epilepsy CME/CE Author Information and Disclosures Release Date: February 29, 2008; Valid for credit through March 1, 2009 | Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.5 nursing contact hours (0.5 contact hours are in the area of pharmacology) | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Recognize the United States Food and Drug Administration (FDA) regulations for generic formulations.
- Discuss the American Academy of Neurology and the American Epilepsy Society position statements on generic drugs to treat
epilepsy.
- Identify the potential advantages and disadvantages of generic antiepileptic drugs for people with epilepsy.
- Evaluate ways that neurologists, primary care providers, pharmacists, and nurses can ensure continuity of care for their patients with epilepsy.
- Educate people with epilepsy about their medications to alleviate any misconceptions or concerns and improve medication adherence.
Authors and Disclosures Michel J. Berg, MD
Disclosure: Michel J. Berg, MD, has disclosed that he has served as an advisor or consultant to Harris Interactive, supported by a grant from GlaxoSmithKline. Barry E. Gidal, PharmD, RPh
Disclosure: Barry E. Gidal, PharmD, RPh, has disclosed that he
has served as an advisor or consultant to GlaxoSmithKline, UCB, and Abbott. Dr. Gidal has also disclosed that he has received honoraria for speaking from GlaxoSmithKline, UCB, and Abbott, and has received grants for clinical research from GlaxoSmithKline and UCB. Christine O'Dell, RN, MSN
Disclosure: Christine O'Dell, RN, MSN, has disclosed that she has served as an advisor or consultant to Valeant
Pharmaceuticals and Questor Pharmaceuticals. Ms. O'Dell has also disclosed that she has received grants for clinical research and for educational activities from Valeant Pharmaceuticals and Questor Pharmaceuticals. Raj D. Sheth, MD
Disclosure: Raj D. Sheth, MD, has disclosed that he has received honoraria for speaking from Jazz, Pfizer, GlaxoSmithKline, Ortho-McNeil Pharmaceuticals, and UCB. Dr. Sheth has also
disclosed that he has received grants for clinical research from GlaxoSmithKline. Stephanie Kushner, PhD
Disclosure: Stephanie Kushner, PhD, has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
This Activity is sponsored by Medscape Continuing Education Provider Unit. Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology. Provider Number: 6FDKKC-PRV-05
Contact This Provider
|
|
